Article
Ecopipam (EBS-101) as a Novel Non-D2 Therapy for Tourette Syndrome: A Systematic Review and Meta-analysis of Prospective Clinical Studies
2026-07-30
Abstract excerpt
<h4>Background: </h4> Tourette syndrome (TS) is a neurodevelopmental disorder characterized by persistent motor and vocal tics. Current treatments mainly target dopamine D2 receptors but are often limited by adverse effects. Ecopipam, a selective dopamine D1 receptor antagonist, has emerged as a potential non-D2 therapeutic alternative. <h4>Methods:</h4> PubMed, Embase, Cochrane Library, Google Scholar, and Clinic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- de2e3637-1a3b-5877-9c11-34d9af9fbdc0
- DOI
- 10.20944/preprints202607.2220.v1
